Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer

Tuesday, Roivant Sciences Ltd. (NASDAQ:ROIV) created Pulmovant to in-license from Bayer AG (OTC:BAYRY) exclusive worldwide rights to develop and commercialize mosliciguat.

Bayer received an upfront cash payment of ~$14 million, with up to an additional $280 million agreed upon for future development, regulatory, commercial milestone payments, and tiered high-single-digit sales-based royalties.

Mosliciguat is an inhaled, once-daily sGC activator with targeted delivery to the lungs via a dry powder inhaler.

Pulmovant presented data from the proof-of-concept Phase 1b ATMOS study during the European Respiratory Society Congress.

Also Read: What’s Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

The ATMOS Phase 1b trial ...